Epiminder Secures Funding and Marks First U.S. Minder Implant as DETECT Study Builds Momentum

Epiminder Ltd. ( (AU:EPI) ) has shared an announcement.

Epiminder has strengthened its capital position in the first half of FY26 through a $125 million capital raise, faster-than-expected R&D tax settlements, favourable foreign exchange movements, and a higher 2026 Medicare reimbursement ruling of US$27,700 for its Minder device, supporting an assumed US$25,000 average selling price. The company says it now has sufficient cash to fund its key programs, including the DETECT reimbursement study and next-generation Minder G1 development, through 2027 and well into 2028.

Operationally, Epiminder achieved the first U.S. implant of its Minder device in January 2026 at the University of Pennsylvania, marking a significant milestone in its DETECT study, which targets 210 patients across up to 25 leading medical centres by March 2027. Nine U.S. centres, including Duke, Yale and Washington University in St Louis, have joined the program, while engineering work on the G1 Minder remains on track for completion by the end of FY27, positioning the company to advance its commercialisation strategy despite expected net cash outflows of about $20 million in the second half of FY26.

More about Epiminder Ltd.

Epiminder Limited is an ASX-listed medical device company focused on breakthrough epilepsy monitoring technology. Its primary product is the FDA-approved Minder implantable device, designed for continuous EEG monitoring to improve diagnosis and management of drug-resistant epilepsy, with a key commercial focus on the U.S. market and reimbursement-led adoption through leading medical centres.

Average Trading Volume: 172,475

Find detailed analytics on EPI stock on TipRanks’ Stock Analysis page.